- Home
- AVXL vs CAPL Comparison
AVXL vs CAPL Comparison
Compare AVXL & CAPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVXL
- CAPL
- Stock Information
- Founded
- AVXL 2004
- CAPL 1992
- Country
- AVXL United States
- CAPL United States
- Employees
- AVXL N/A
- CAPL N/A
- Industry
- AVXL Biotechnology: Biological Products (No Diagnostic Substances)
- CAPL Oil Refining/Marketing
- Sector
- AVXL Health Care
- CAPL Energy
- Exchange
- AVXL Nasdaq
- CAPL Nasdaq
- Market Cap
- AVXL 956.7M
- CAPL 793.6M
- IPO Year
- AVXL N/A
- CAPL 2012
- Fundamental
- Price
- AVXL $9.48
- CAPL $20.40
- Analyst Decision
- AVXL Strong Buy
- CAPL
- Analyst Count
- AVXL 2
- CAPL 0
- Target Price
- AVXL $44.00
- CAPL N/A
- AVG Volume (30 Days)
- AVXL 994.2K
- CAPL 24.1K
- Earning Date
- AVXL 08-12-2025
- CAPL 11-05-2025
- Dividend Yield
- AVXL N/A
- CAPL 10.23%
- EPS Growth
- AVXL N/A
- CAPL 100.77
- EPS
- AVXL N/A
- CAPL 1.13
- Revenue
- AVXL N/A
- CAPL $3,522,840,000.00
- Revenue This Year
- AVXL N/A
- CAPL N/A
- Revenue Next Year
- AVXL N/A
- CAPL N/A
- P/E Ratio
- AVXL N/A
- CAPL $18.22
- Revenue Growth
- AVXL N/A
- CAPL N/A
- 52 Week Low
- AVXL $4.93
- CAPL $19.50
- 52 Week High
- AVXL $14.44
- CAPL $25.73
- Technical
- Relative Strength Index (RSI)
- AVXL 47.45
- CAPL 42.95
- Support Level
- AVXL $8.82
- CAPL $20.30
- Resistance Level
- AVXL $10.40
- CAPL $20.67
- Average True Range (ATR)
- AVXL 0.52
- CAPL 0.49
- MACD
- AVXL 0.04
- CAPL -0.03
- Stochastic Oscillator
- AVXL 48.68
- CAPL 19.11
About AVXL Anavex Life Sciences Corp.
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066.
About CAPL CrossAmerica Partners LP Common Units representing limited partner interests
CrossAmerica Partners LP is engaged in the wholesale distribution of motor fuel and the ownership and leasing of real estate used in the retail distribution of motor fuel. The company operates through two business segments namely Wholesale and Retail. The Wholesale segment is a key revenue driver and includes the wholesale distribution of motor fuel to lessee dealers, independent dealers, commission agents, DMS, Circle K, and through company-operated retail sites. The Retail segment includes the sale of convenience merchandise items, the retail sale of motor fuel at company-operated retail sites, and the retail sale of motor fuel at retail sites operated by commission agents.